Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
12 September 2023 - 2:05PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO
RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of September 2023
Commission File Number 001-37381
MEDIGUS LTD.
(Translation of registrant’s name into English)
10 HaNechoshet Street Tel-Aviv, 6971072, Israel
(Address of principal
executive offices)
Indicate by check mark whether the registrant files or will file annual
reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form
40-F ☐
EXPLANATORY NOTE
On September 12, 2023, Medigus
Ltd. issued a press release titled: “Medigus to Increase its Share in AI Systems to 36%.” A copy of this press release is
furnished herewith as Exhibit 99.1
EXHIBIT INDEX
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
|
MEDIGUS LTD. |
|
|
|
Date: September 12, 2023 |
By: |
/s/ Tali Dinar |
|
|
Tali Dinar |
|
|
Chief Financial Officer |
3
Exhibit 99.1
Medigus
to Increase its Share in AI Systems to 36%
Tel Aviv, Israel, Sept. 12, 2023 (GLOBE NEWSWIRE)
-- Medigus Ltd. (Nasdaq: MDGS), a technology company engaged in advanced medical solutions, innovative internet technologies
and electric vehicle and charging solutions, announced today that on September 5, 2023, AI Systems Ltd. (“AI Systems”) approved
the conversion of a $1,240 thousand (4.75 million NIS) convertible loan of the Company into shares of AI Systems. Following the conversion,
Medigus will hold a 36% stake in AI Systems and become its largest shareholder.
AI Systems, a technology company traded on the
Tel Aviv Stock Exchange (TASE), is in negotiations to merge new activity and further expand its technological endeavors.
This conversion of the convertible loan to
shares solidifies Medigus’ commitment to diversify its investments with AI - based technologies and nurture its relationships
with cutting-edge technology companies.
About Medigus
Based in Israel, Medigus Ltd. (Nasdaq: MDGS) is
a technology company focused on innovative growth partnerships, mainly in advanced medical solutions, digital commerce and electric vehicle
markets. Medigus’ affiliations in the medical solutions arena include ownership in Polyrizon Ltd.. The Company’s affiliates
in digital commerce include Gix Internet Ltd., Jeffs’ Brands Ltd. and Eventer Technologies Ltd. In the electric vehicle market,
Charging Robotics Ltd. and Revoltz Ltd. by way of Fuel Doctor Holdings, Inc., are also part of the Company’s portfolio of technology
solution providers. Medigus is traded on the Nasdaq Capital Market. To learn more about Medigus’ advanced technologies, please visit http://www.medigus.com/.
Cautionary Note Regarding Forward Looking
Statements
This press release contains forward-looking statements
within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal
securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,”
“seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking
statements. Because such statements deal with future events and are based on Medigus’ current expectations, they are subject to
various risks and uncertainties, and actual results, performance or achievements of Medigus could differ materially from those described
in or implied by the statements in this press release.
The forward-looking statements contained or implied
in this press release are subject to other risks and uncertainties, including those discussed in any filings with the SEC. Except as otherwise
required by law, Medigus undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events
or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been
provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Medigus
is not responsible for the contents of third-party websites.th
Company Contact:
Tali Dinar
Chief Financial Officer
+972-8-6466-880
ir@medigus.com
Medigus (NASDAQ:MDGS)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
Medigus (NASDAQ:MDGS)
Historical Stock Chart
Von Jun 2023 bis Jun 2024